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Introduction
To this day, malignant, deeply seated brain tumors 
constitute an all but impossible challenge to curative 
treatment, even with state of the art multimodal therapeutic 
regimes, including neurosurgery, chemo- and radiotherapy. 
Tumor recurrence is almost unavoidable and often within 
months after diagnosis patients must be declared as 
inoperable, leaving them in a desperate condition with 
palliative care. Contemporary brain tumor surgery aims 
at substantial cytoreduction to achieve temporary tumor 
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control, but is limited by a delicate compromise between 
aggressive tumor eradication and cautious preservation of 
patient brain functionality. Survival of brain tumor patients 
is therefore greatly influenced by the location, i.e., the 
operability of the tumor. Novel approaches to complement 
conventional surgery for safe tumor reduction are urgently 
needed and would benefit a large patient population.
Focused ultrasound has the potential to be the core 
technology for such an alternative. Owing to the complex 
physical and chemical phenomena that can be elicited by 
suitably parameterized acoustic fields in living tissue, a wide 
range of medical applications of ultrasound have emerged 
both for diagnostic and for therapeutic purposes. In the 
field of neurology particularly researchers were enthusiastic 
about the potential application of high intensity focused 
ultrasound (HIFU) for non-invasive thermal ablation of 
diseased brain tissue. However, it became evident early on, 
that transmitting ultrasound through the intact skull was 
a challenging task and that the margin between successful 
tissue ablation in the target and adverse effects on the way 
to target was very small (1). Ground breaking work on the 
way to clinical exploitation of HIFU for brain surgery was 
done by Lynn, Fry and colleagues in the 1950s producing 
reversible and irreversible lesions in the brain in preclinical 
animal models (2-6), and subsequently by Meyers, Fry, 
Heimburger and colleagues in the sixties and seventies in 
patients (7-9). Heimburger succeeded in treating patients 
suffering both from functional brain disorders and from 
brain tumors using an open skull approach, where he 
sonicated through a bone window after craniotomy. Taking 
advantage of the lack of ionizing radiation in HIFU 
treatments he even repeatedly treated tumor recurrence 
in some of his patients and achieved survival times in 
patients diagnosed with glioblastoma multiforme (GBM) 
of up to 13 years. However, lacking a suitable modality for 
reliable image guidance of these interventions the outcome 
of treatments was unpredictable and adverse events were 
difficult to control. Ultimately, Heimburger was recognized 
as a pioneer of the field who unfortunately was ahead of his 
time (9-12).
Major technological and methodological developments 
were needed to make non-invasive neurosurgery by 
transcranial focused ultrasound a clinical reality: the 
development of MR-compatible, large phased array 
transducers (13,14) to create high-energy acoustic fields 
with precise spatial phase control; numeric modeling of 
ultrasound-bone- interaction to allow for predictable 
transmission of acoustic energy through the intact skull 
bone (15,16); proton-resonance frequency shift MR 
thermometry (17) to monitor the acoustic heating process 
at the target; and system integration into clinical treatment 
platforms that provided both technical precision and 
robustness, as well as user friendly process control and 
workflow management. 
Clinical translation of these innovations resparked 
interest in HIFU neurosurgery in the late 1990s when 
magnetic resonance imaging was proposed as a modality 
capable of providing closed-loop image-guidance to the 
HIFU intervention process, i.e., of allowing for MR-based 
intraoperative target delineation, local risk assessment, 
monitoring of lesion creation and validation of intervention 
endpoint. In 2006, using a commercial HIFU system 
designed for the treatment of uterine fibroids Ram and 
colleagues (11) could demonstrate the feasibility of safely 
ablating malignant brain tumors by MR imaging guided 
focused ultrasound (MRIgFUS) in three patients, although 
their approach still relied on a craniotomy for undisturbed 
acoustic access to the target volume. Around that time, the 
solution to this problem, namely the technical approach to 
focus acoustic energy through the human skull with high 
enough focal gain to allow for tissue ablation in the target 
volume without overheating the bone and adjacent brain 
tissue was tested by the group of Ferenc Jolesz, BWH 
Boston, in a cohort of three patients suffering from centrally 
located glioblastomas. Using a 500-element large phased 
array transducer, a water bolus between transducer surface 
and patient skull for acoustic coupling and skull cooling, 
and CT-based acoustic modeling of the skull bone induced 
phase aberration for individual correction of transducer 
element phase they succeeded in generating significant local 
heating in the tumors of all patients (18). Unfortunately, the 
treatments could not achieve verifiable tumor ablation and 
revealed the need for phased array transducers with even 
more elements and higher acoustic power output to conduct 
therapeutically effective brain treatments. 
While technically successful, both the Ram and the 
McDannold studies revealed significant limitations of the 
available ultrasound technology for brain tumor ablation, 
namely the vulnerability of brain tumor vasculature under 
high mechanical stress as induced by focused ultrasound; 
significant geometrical restrictions to the accessible 
intracranial space (limited treatment envelope) imposed by 
the physics of acoustic waves in the applied frequency range 
of 650 kHz; and the inherently slow ablation rate dictated by 
long cooling delays between successive sonications to avoid 
adverse thermal effects in skull bone and adjacent tissues. 
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In 2008, Martin and colleagues (19) identified functional 
neurosurgery as a class of indications that would better 
harness the lesioning precision achievable with transcranial 
MRIgFUS (tcMRIgFUS) while avoiding the inherent 
difficulties of brain tumor treatments. Most stereotactic 
targets applied in functional neurosurgery are located in 
the center of the brain (within the treatment envelope) and 
basically represent healthy, non-pathological brain tissue, 
but with functional deficits. Using the newest generation 
of InSightec’s Neuro tcMRIgFUS treatment platform 
this phase I study demonstrated the feasibility and safety 
of tcMRgFUS for functional neurosurgery in a cohort of 
nine patients suffering from chronic neuropathic pain. 
The reason for choosing chronic pain as a pilot application 
was based on the fact that the central lateral nucleus 
of the thalamus applied in this study is relatively large 
(4×4×12 mm), has some margin to vulnerable neighboring 
neurological structures and is located in the unspecific 
thalamus, where lesioning is not expected to cause loss 
of specific neurological functions. This data was later on 
complemented (20), the indication extended by studies 
for Essential Tremor (21,22), Parkinson’s disease (23) and 
neuro-psychiatric disorders (24) and provided the basis for 
the CE marking of the ExAblate Neuro as a medical device 
by the end of 2012. To date, several clinical phase I and II 
trials investigate the feasibility and safety of tcMRIgFUS 
for functional neurosurgery and report encouraging results 
(19-21,25).
Clinical experience
In 2010, motivated by the convincing technical performance 
of the InSightec Neuro platform in functional neurosurgery, 
the researchers at the FUS Center in Zurich, Switzerland, 
decided to resume work on the non-invasive treatment of 
brain tumors. A phase I open-label, prospective clinical 
trial was implemented to assess the feasibility and safety of 
treating patients suffering from centrally located, freshly 
diagnosed or recurrent gliobastoma, or brain metastases of 
breast and lung cancers. The study protocol was approved 
by the involved Ethics Committees and by SwissMedic 
(ClinicalTrials.gov NCT01698437). 
The confidence to finally success in this endeavor that 
had driven HIFU development for so many years was 
mainly based on the significant technical improvements 
that had been implemented in the ExAblate Neuro since 
the Boston study in 2006 (18). For technical performance, 
the system is still operating at 650 kHz but uses a more 
powerful 1024-element transducer to achieve the focal gain 
needed to reliably ablate tissue in the target volume (26). 
For improved image guidance, it is now integrated into 3T 
MR-scanners and can be complemented with dedicated 
MR-coils for optimized MR quality (27). For intervention 
safety, the patients are immobilized with a stereotactic 
frame, instead of a face mask and, most importantly, 
integrated passive cavitation detectors interrupt treatment 
sonications whenever acoustic signatures indicative of 
inertial cavitation are detected.
Technical constraints and today’s GCP standards 
impose strong filtering criteria on patient selection in this 
ongoing study. Because of the restricted intracranial volume 
accessible to acoustic focusing only patients being diagnosed 
with centrally located, ideally thalamic brain tumors, are 
candidates for this study. It is our experience that this 
selection criterion severely limits patient admission to this 
study. Moreover, preoperative MR screening has to confirm 
the technical feasibility of the planned intervention and has 
to exclude critical risks for intraoperative hemorrhage by 
identifying vascularity in and around the tumor. Previous 
treatments should not have created contraindications for 
MR imaging by inserting non-MR-safe implants, or for 
FUS treatment by inducing significant cysts, scar tissue or 
calcifications in the proximity of the target. The planned 
FUS intervention should not compromise the current 
therapeutic regime; and the targeted tumor tissue should 
not be too far advanced in necrotic decay and liquefaction, 
so as to allow for reliable MR thermometry. The patient’s 
condition has to be stable with a Karnofsky score above 70. 
As a consequence, during a 4-year screening period only 
three patients with a glioblastoma meeting all inclusion and 
exclusion criteria of the study protocol could be identified 
by the two neuro-oncology centers involved in this project, 
of which only two could be enrolled in the study with fully 
informed written consent.
The tcMRIgFUS intervention process has been described 
in detail elsewhere (28). In short, on the treatment day a 
stereotactic frame is fixated to the patient’s head under local 
anesthesia for intraoperative immobilization. The patient 
is positioned on the MR-table but remains fully awake and 
responsive during the whole intervention procedure (Figure 1).
Repeated neurological assessments before, during 
and after the intervention ensure stable neurological 
conditions and allow to detect treatment related adverse 
neurological symptoms. Paracetamol or ondansetron can be 
administered prophylactically to prevent pain or nausea, if 
needed. After mechanically aligning the geometric center 
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of the transducer with the tumor volume to be ablated, the 
space between the transducer and the patient scalp is sealed 
with a flexible membrane and filled with cooled, degassed 
water. T2- and T1-weighted (T1W) anatomical MR images 
are acquired to register the FUS system coordinate space 
into the MR coordinate space. To clearly visualize the 
anatomical features of the tumor, pre-operatively acquired 
contrast enhanced T1 weighted MR images (T1W + C) are 
also registered. Furthermore, a pre-operatively acquired 
high resolution CT data set of the patient head is registered 
to the MR images for subsequent acoustic modeling and 
correction of skull induced acoustic distortions by the FUS 
system software. Thermal tissue ablation is achieved by 
transmitting pulses of focused ultrasound (sonications) of 
10-25 seconds duration and 150-1,000 Watt acoustic power 
into the targeted tumor tissue where acoustic attenuation 
converts acoustic energy into heat. Since a substantial 
part of the transmitted acoustic energy is absorbed in the 
patient skull cooling periods of several minutes are required 
between sonications to prevent adverse thermal lesions in 
the scalp, the skull bone, or the meninges. Sonication target 
coordinates and sonication parameters, such as duration 
and acoustic power, are individually prescribed in the FUS 
system user interface after careful evaluation of pre- and 
intraoperative MR images and thermal results of previously 
applied sonications. For safety reasons, we decided to 
sonicate primarily viable centrally located tumor tissue that 
does not involve functionally significant eloquent structures, 
although we are aware of the fact that for complete tumor 
eradication the peripheral area beyond the gadolinium 
enhancing tumor volume, i.e., the penumbra, where cancer 
cells are invading healthy brain tissue should be included into 
the treatment volume. The total duration of tcMRIgFUS 
interventions generally lasts between 4 and 5 h. In this study, 
follow-up assessment includes neurological examinations 
and MR imaging immediately following the operation, and 
at 2, 30 and 90 days thereafter. 
Treatment 1
Patient 1 (32 years old, male) was referred to the 
neurosurgical department because of a cystic mass in the 
left sided thalamus extending into the ipsilateral cerebral 
peduncle. Neuroradiological workup and stereotactic 
biopsy classified the tumor as a grade IV, wild type GBM. 
Due to central location and infiltration of the left thalamus 
the tumor was considered to be inaccessible for resection 
by classical neurosurgery and the patient received chemo- 
and radiotherapy. Despite therapeutic efforts the tumor 
continued to grow rapidly and subsequently blocked the 
circulation of the CSF requiring a ventriculo-peritoneal (vp) 
shunt. In April 2012, when the tumor size/volume reached 
5 cm × 7 cm/75 cc , respectively, the tumor board proposed 
the patient as a potential candidate for participation in our 
tcMRIgFUS phase I tumor study.
Planning of the tcMRIgFUS treatment was complicated 
by a vp shunt whose tip was situated close to the target 
volume and its drainage line on the scalp that had to be 
excluded from the sonication pathway (Figure 2).
The treatment started successfully according to protocol 
but stalled during focal spot localization. Although up to 
450 W acoustic power were applied during sonications 1 
through 8, a power setting that is supposed to induce focal 
heating up to 54 ℃ according to our previous treatment 
experience, MR thermometry failed to measure correct 
thermal rise. Therefore, lacking reliable temperature 
monitoring the treatment was prematurely terminated for 
safety reasons. 
Post intervention analysis of CT, MR imaging and MR 
thermometry data led to the conclusion that the tip of the 
shunt contained a small ferromagnetic contamination. The 
local B0 inhomogeneity induced by this particle caused 
significant off-resonance effects in the MR signal that 
resulted in unreliable thermal measurements. Nevertheless, 
while the patient’s chemotherapeutic regimens were kept 
Figure 1 tcMRIgFUS treatment setup: the patient’s head is 
immobilized by a stereotactic frame a positioned in the transducer. 
A flexible membrane seals the water filled volume between patient 
head and transducer.
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unchanged as required by his treatment protocol, no further 
tumor progression could be detected during the following 
10 months. The patient’s overall clinical presentation 
improved and allowed him to leave the hospital, return to his 
family and even to resume professional work part time again.
Treatment 2
After a 10-month period of well-being of patient 1, the 
tumor began to regrow again. A second tcMRIgFUS 
intervention was attempted in February 2013. Sadly, on the 
day of the intervention the clinical condition of the patient 
had deteriorated so much that he could not tolerate the 
motionless supine position required for the procedure for an 
extended period of time. Even though a peak temperature 
of 47 ℃ could be achieved the procedure had to be aborted 
prematurely, again without resulting in tumor ablation.
Treatment 3
Patient 2 (63 years old, male) presented with a rapidly 
growing recurrent tumor in the left thalamic and 
subthalamic region 5 years after first surgical resection 
of a GBM in the temporal lobe. The location of the 
recurrent tumor in eloquent brain areas precluded surgical 
reevaluation. The patient’s neurological symptoms included 
a right-sided facio-brachio-crural hemiparesis and a slight 
esophoria with ptosis of the right eye. In a preoperative 
MR-angiogram pronounced vascularization of the tumor 
regions could be excluded, and thus, the tumor board 
proposed a tcMRIgFUS intervention.
The treatment was conducted in March 2014 (29) 
according to the study protocol. A total of 25 sonications 
were applied with up to 19,550 Joules of acoustic energy, of 
which 17 reached ablative temperatures of over 55 ℃ with a 
maximum of 65 ℃, as recorded by intra-operative real-time 
MR thermometry (Figure 3).
According to the purpose of the clinical study, the treatment 
was ended when intra-operative real-time MR thermometry 
and calculated thermal dose maps predicted successful ablation 
of a substantial volume of the tumor tissue, thereby having 
established the clinical feasibility of the procedure.
MR images acquired immediately after the intervention 
revealed multiple isolated hyperintense lesions on diffusion 
tensor MR images (DTI) in the sonicated tumor part. No 
signs indicative of intracranial hemorrhage or perifocal 
edema at the sites of presumably ablated tissue were visible. 
On day 5 comparison of pre- and post-operative, contrast 
enhanced T1-weighted MRI confirmed initial DTI findings 
and revealed new, well defined areas of non-enhancing, and 
thus non perfused, coagulated tumor tissue showing high 
DTI signals as expected (Figure 4).
The cumulative ablated tumor volume calculated by manual 
delineation on T1W+C MRI was 0.7 cc corresponding to 
Figure 2 Intraoperative axial MRI from treatment 1: the tumor 
mass is hypointense in the center of the image pushing against the 
ventricles. The small circle highlights the sonication target; 15 mm 
lateral to the shunt line, which is demarcated.
Figure 3 Preoperative T1W + C axial MRI from treatment 3 
depicting the tumor as hyperintense mass with thermal dose maps 
overlaid. The gray trapezoidal shape demarks tumor volume 
considered to be ablated. The box with cross in the middle 
highlights the target of the next sonication.
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Figure 4 Comparison pre-/post-operative T1W + C axial MRI from treatment 3. Lower row preoperative, upper row postoperative. New 
non-perfused tissue volumes due to tissue ablation are clearly distinguishable.
10% of the enhancing tumor volume of 6.5 cc. Neurological 
examination on day 5 post-op revealed an improvement of 
the patient’s general condition compared the preoperative 
state with a substantial amelioration of the hemiparesis 
of his right arm and a resolution of the ptosis of his right 
eyelid. No treatment related neurological adverse effects 
were observed. Repeated follow-up examinations until 
the time of writing this report, 6 months after the HIFU 
intervention, find unchanged patterns of ablated tumor 
tissue and no signs of tumor progression. The patient 
enjoys a reasonably good health condition and is partially 
ambulant at home together with his family.
Discussion
Both, the failures in treatments 1 and 2, and the success 
in treatment 3 teach us important lessons on the clinical 
potential of tcMRIgFUS for brain tumor ablation. 
In the first two interventions the treatment team 
was confronted with the full spectrum of comorbidities 
typically associated with advanced brain tumor progression 
and which, notably, are mostly avoided by functional 
tcMRIgFUS neurosurgery. Brain tumor patients in 
advanced stage are often in a precarious clinical state while 
the tcMRIgFUS intervention requires the patients to stay 
immobilized in supine position in the MR bore for several 
hours keeping awake for neurological monitoring. They 
carry artifacts of previous and current treatments such 
as scars, calcifications, bone replacements, subcutaneous 
device for drug delivery, shunts, clips and other implants 
while the acoustic path to the target volume should be free 
of absorbing or scattering materials and no MRI-unsafe or 
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MRI distorting implants should be present. The limitations 
imposed by these conditions might be alleviated through 
sophisticated anesthesiological management and adapted 
treatment and imaging protocols, but ultimately they will 
be hard to overcome.
Accordingly, the success in treatment 3 can be attributed 
largely to the fact that the patient presented in a reasonably 
good clinical condition and was referred to tcMRIgFUS 
with a freshly diagnosed, but rapidly growing recurrent 
tumor after years of chemotherapy only, thus offering 
an operation field that was, acoustically speaking, not 
compromised by earlier treatments. Still, even under these 
optimal conditions the total ablation volume achieved in 
the 4 h treatment session was only 0.7 cc, i.e., only 10% 
of the enhancing tumor volume, and not nearly sufficient 
for significant cytoreduction as is believed to be the key 
for sustained tumor control. Even though the reduction 
of space-occupying and displacing effects of the tumor 
mass resulted in immediate improvement of neurological 
condition and quality of life for the patient, the unfavorable 
relationship between achievable ablation volume per 
sonication and total tumor volume suggests the application 
of tcMRIgFUS mostly for local tumor control.
Nevertheless, treatment 3 also confirmed the expected 
benefits of tcMRIgFUS as a non-invasive, fully image 
guided and controlled thermal intervention modality. 
Precise intraoperative MR image guidance allowed to 
selectively target viable gadolinium enhancing tumor 
tissue and to operate in close vicinity of the tumor border. 
Eloquent neurological structures could be spared and 
collateral damage avoided by integrating anatomical 
information provided by preoperative high-resolution 
MRI. Although thermal lesions are induced immediately 
through deposited acoustic energy local anatomy is not 
distorted by the lesions and therefore, preoperative 
structural or physiological data registered into the FUS 
coordinate system remains valid throughout the procedure. 
In contrast to classical surgical interventions, repeated 
examinations of the fully awake and communicating 
patient allowed to assure the integrity of his neurological 
status during the entire tcMRIgFUS intervention and 
immediately thereafter. Treatment progress could be 
monitored by intraoperative MR thermometry and 
thermal dose maps predicted treatment outcome. Owing 
to the non-invasive approach of tcMRIgFUS the patient 
could leave the hospital on his own wish on day 2 after 
the intervention in an even better condition than before. 
This is all the more remarkable as the intervention had 
thermally deactivated significant portions of tumor 
tissue. The risk of allowing the patient to leave the 
hospital so early was mitigated by careful post-operative 
neuroradiological workup that allowed to unambiguously 
evaluate the thermal lesions which, in contrary to radiation 
necrosis, appear immediately after the sonications and 
are known to be stable in size, or even shrink over time. 
Finally, since tcMRIgFUS does not involve ionizing 
radiation the treatment 3 can be repeated if needed, i.e., 
the patient is, in accordance with the clinical protocol, 
eligible for further global tumor mass reduction or local 
control of resumed tumor growth by tcMRIgFUS if 
considered indicated by the tumor board.
The clinical status of the second patient after treatment 
3 up to the time of writing this report is remarkable. 
Together with his improved neurological condition a 
complete stop of volume increase or progression of the 
previously rapidly growing tumor is observed. Lacking 
histological or biochemical evidence for local physiological 
reactions, one can only speculate about the reasons for this 
observation and its duration. Potential explanations are 
a local sensitization of tumor cells to the chemotherapy 
in proximity to ablation sites by physiological effects 
similar to hyperthermia; a temporary increase in the local 
concentration and thus the efficacy of the currently used 
chemotherapeutic agent owing to transient heat induced 
opening of the blood brain and blood tumor barriers 
around the sonication sites; or a systemic anti-tumor 
response triggered by presenting tumor antigens from 
thermally damaged tumor cells to the immune system 
as is reported from thermal ablation of tumors (30). We 
consider this to be an important clinical observation 
that relates to earlier reports from Heimburger (9) 
and Ram (11) describing prolonged survival of patients 
with malignant gliomas after HIFU interventions. 
Hyperthermia is known to regulate various molecular 
aspects of the immune response (31,32). Therefore, HIFU 
induced whole or even partial tumor cell necrosis by heat 
coagulation or hyperthermia, respectively, may well induce 
different anti-tumor responses by the innate and adaptive 
immune system. Tentative evidence for such HIFU-
augmented specific host anti-tumor immune response 
can be found in experimental (33-38) and clinical reports 
(9,11,39). In addition, similar observations are reported for 
extracranial, solid tumors (40-42), including regression or 
even complete resolution of distant untreated tumors and 
metastases after partial thermal ablation or cryo-therapy 
[for review see (43)]. 
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Conclusions
The preliminary technical and clinical results of the three 
tcMRIgFUS treatments conducted so far in this ongoing 
study demonstrate that noninvasive focused ultrasound 
interventions for brain tumors can be safely carried out 
and can create clinical benefits for the patient. They also 
illustrate how targeting and lesioning precision exploited 
so far only in functional tcMRIgFUS neurosurgery 
creates a clinical benefit in tumor treatments too: specific 
areas of the tumor and in particular the tumor border 
can be ablated accurately whereas supposedly eloquent 
areas in the penumbra of the tumor can be spared. Also, 
while tcMRIgFUS suffers from severe restrictions in the 
accessible brain volume in the periphery of the brain, e.g., 
in the cerebral cortex, it can safely access deep seated brain 
tumors not amendable for conventional neurosurgery 
without inflicting collateral damage on the way to the 
target. These encouraging results reinforce the huge 
expectations towards HIFU as a new core technology for 
neurological applications. However, both the failures in 
treatments 1 and 2 under very difficult conditions, and the 
success in treatment 3 under optimal conditions show that 
there is still a wide gap to widespread clinical application. 
Substantial technical challenges, such as widening the 
accessible brain area or increasing the achievable ablation 
volume per treatment time remain to be overcome in order 
to establish tcMRIgFUS as a prevailing neurosurgical 
modality for brain tumor treatment. Technical evolution 
will show whether it will become a versatile tool for bulk 
tumor ablation or a specialist tool for ablation of residual 
tumor foci after classical resection. 
While context and available space have limited this 
account to clinical experience with HIFU for thermal 
ablation of brain tumors, clinical translation of pulsed 
low intensity ultrasound and systemically administered 
microbubbles for transient opening of the blood brain 
barrier for targeted drug delivery into the brain parenchyma 
is imminent and has the potential to constitute radically 
new treatment paradigms (44,45). Such new paradigms 
will ultimately be based on variations of the tcMRIgFUS 
technology described here. Exploiting not only the thermal 
effects of ultrasound but the whole spectrum of physical 
and physiological reactions observed in the interaction of 
ultrasound with living cells to treat brain tumors will be 
again a long endeavor requiring interdisciplinary research 
through a wide range of natural science, medicine and 
engineering disciplines.
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